United Therapeutics enters $477.6M accelerated share repurchase
Sep 8, 11:50 AM
UTHR
- United Therapeutics Corporation (UTHR) has a strong buy recommendation rating due to its strategic financial decision-making.
- The company plans to utilize the remaining funds from a $2 billion share repurchase authorization to enhance shareholder value.
- An accelerated share repurchase agreement with Citibank will facilitate the purchase of approximately $477.6 million worth of its common stock.
Recommendation Rating: Strong Buy
United Therapeutics Corporation (UTHR) has announced plans to fully utilize the remaining funds from its previously disclosed $2 billion share repurchase authorization. To implement this plan, the company will engage in an accelerated share repurchase agreement with Citibank, aimed at purchasing approximately $477.6 million worth of its common stock.